Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Long-acting benzodiazepine with properties similar to diazepam.
Indicated in anxiety disorder and insomnia.
Oral administration two to three times per day.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight, not high protein binding, prolonged elimination time and being very lipophilic) make it probable that it will pass to milk in an amount that could be significant.
No problems have been observed in infants whose mothers took it (Kelly 2012).
There is a case described coinciding with sudden death of a 23-day-old infant with risk factors, without assuring causality (Anderson 2003 -> Martens 1994).
Bromazepam does not alter prolactin levels (D'Armiento 1981).
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
Choose short-acting benzodiazepines and use the lowest effective dose (Rowe 2013), especially during the neonatal period and in prematurity, as they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and adequate feeding of the infant.
Bed-sharing with the baby is not recommended if this medicine is being taken due to increased risk of suffocation or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).